Clinical Trial Update: Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a combination of docetaxel, carboplatin, and rucaparib camsylate in metastatic castration-resistant prostate cancer with homologous r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Rucaparib camsylate (rucaparib camsylate)

Snippet

Sponsor: University of Washington | Conditions: ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Status: TERMINATED